View All Documents & Correspondence
Methods For Culturing Mesenchymal Stem Cells, Compositions And Implementations Thereof
Abstract: There is provided herein methods generating a population of primed mesenchymal stem cell-derived exosomes. A method in accordance with the disclosure may comprise expanding a population of mesenchymal stem cells (MSCs) in culture; administering one or more priming agents in the culture to prime the population of MSCs and obtain a population of primed MSCs; growing the population of the primed MCSs in culture to produce a primed-MSC-derived conditioned medium; collecting the primed MSC-conditioned medium; and purifying a population of exosomes from the primed MSC-conditioned medium. The one or more priming agents may comprise a conditioned media derived from a population of stem cells different from the population of MSCs, a Nrf2 activator, or a combination thereof. There is also provided herein methods of treating tissues such as cornea and liver using the population of exosomes from the primed MSC-conditioned medium.
Notices, Deadlines & Correspondence
Patent Information
Applicants
PANDORUM TECHNOLOGIES PRIVATE LIMITED
Inventors
1. BHOWMICK, Tuhin
2. CHANDRU, Arun
3. THOMAS, Midhun Ben
4. SENGUPTA, Suman
5. MENON, Deepthi
6. KARUNAKARAN, Wenson Rajan David
7. SELVAM, Shivaram
Specification
There is provided herein methods generating a population of primed mesenchymal stem cell-derived exosomes. A method in accordance with the disclosure may comprise expanding a population of mesenchymal stem cells (MSCs) in culture; administering one or more priming agents in the culture to prime the population of MSCs and obtain a population of primed MSCs; growing the population of the primed MCSs in culture to produce a primed-MSC-derived conditioned medium; collecting the primed MSC-conditioned medium; and purifying a population of exosomes from the primed MSC-conditioned medium. The one or more priming agents may comprise a conditioned media derived from a population of stem cells different from the population of MSCs, a Nrf2 activator, or a combination thereof. There is also provided herein methods of treating tissues such as cornea and liver using the population of exosomes from the primed MSC-conditioned medium.
Documents
Application Documents
| # | Name | Date |
|---|---|---|
| 1 | 202447016617-STATEMENT OF UNDERTAKING (FORM 3) [07-03-2024(online)].pdf | 2024-03-07 |
| 2 | 202447016617-NOTIFICATION OF INT. APPLN. NO. & FILING DATE (PCT-RO-105-PCT Pamphlet) [07-03-2024(online)].pdf | 2024-03-07 |
| 3 | 202447016617-FORM 1 [07-03-2024(online)].pdf | 2024-03-07 |
| 4 | 202447016617-DRAWINGS [07-03-2024(online)].pdf | 2024-03-07 |
| 5 | 202447016617-DECLARATION OF INVENTORSHIP (FORM 5) [07-03-2024(online)].pdf | 2024-03-07 |
| 6 | 202447016617-COMPLETE SPECIFICATION [07-03-2024(online)].pdf | 2024-03-07 |
| 7 | 202447016617-FORM-26 [06-06-2024(online)].pdf | 2024-06-06 |
| 8 | 202447016617-Proof of Right [19-06-2024(online)].pdf | 2024-06-19 |
| 9 | 202447016617-FORM 3 [21-08-2024(online)].pdf | 2024-08-21 |
| 10 | 202447016617-FORM 18 [08-08-2025(online)].pdf | 2025-08-08 |
| 11 | 202447016617-MARKED COPIES OF AMENDEMENTS [14-08-2025(online)].pdf | 2025-08-14 |
| 12 | 202447016617-FORM 13 [14-08-2025(online)].pdf | 2025-08-14 |
| 13 | 202447016617-AMMENDED DOCUMENTS [14-08-2025(online)].pdf | 2025-08-14 |